Telinavir | CAS#143224-34-4 | anti-HIV aspartyl protease inhibitor

MedKoo Cat#: 462058 | Name: Telinavir

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Telinavir is an anti-HIV aspartyl protease inhibitor which was in phase II clinical development with Searle (Monsanto) in the USA.

Chemical Structure

Telinavir

CAS#143224-34-4

Theoretical Analysis

MedKoo Cat#: 462058

Name: Telinavir

CAS#: 143224-34-4

Chemical Formula: C33H44N6O5

Exact Mass: 604.3373

Molecular Weight: 604.75

Elemental Analysis: C, 65.54; H, 7.33; N, 13.90; O, 13.23

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Telinavir; SC 52151; SC-52151; NSC 670881

IUPAC/Chemical Name

Butanediamide, N1-((1S,2R)-3-((((1,1-dimethylethyl)amino)carbonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2S)-

InChi Key

ZILOOGIOHVCEKS-HZFUHODCSA-N

InChi Code

InChI=1S/C33H44N6O5/c1-21(2)19-39(32(44)38-33(3,4)5)20-28(40)26(17-22-11-7-6-8-12-22)36-31(43)27(18-29(34)41)37-30(42)25-16-15-23-13-9-10-14-24(23)35-25/h6-16,21,26-28,40H,17-20H2,1-5H3,(H2,34,41)(H,36,43)(H,37,42)(H,38,44)/t26-,27-,28+/m0/s1

SMILES Code

CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)c2ccc3ccccc3n2)C(=O)NC(C)(C)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 604.75 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: SC-52151, a novel inhibitor of the human immunodeficiency virus protease. M Bryant, D Getman, M Smidt, J Marr, M Clare, R Dillard, D Lansky, G DeCrescenzo, R Heintz, K Houseman, et al. Antimicrob Agents Chemother. 1995 Oct; 39(10): 2229–2234. doi: 10.1128/aac.39.10.2229 PMCID: PMC162920 2: Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. L Moutouh, J Corbeil, D D Richman Proc Natl Acad Sci U S A. 1996 Jun 11; 93(12): 6106–6111. doi: 10.1073/pnas.93.12.6106 PMCID: PMC39197 3: Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. R E Rose, Y F Gong, J A Greytok, C M Bechtold, B J Terry, B S Robinson, M Alam, R J Colonno, P F Lin Proc Natl Acad Sci U S A. 1996 Feb 20; 93(4): 1648–1653. doi: 10.1073/pnas.93.4.1648 PMCID: PMC39996 4: A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. M L Smidt, K E Potts, S P Tucker, L Blystone, T R Stiebel, Jr, W C Stallings, J J McDonald, D Pillay, D D Richman, M L Bryant Antimicrob Agents Chemother. 1997 Mar; 41(3): 515–522. PMCID: PMC163743 5: Comparison of Human Immunodeficiency Virus Type 1 Pr55Gag and Pr160Gag-Pol Processing Intermediates That Accumulate in Primary and Transformed Cells Treated with Peptidic and Nonpeptidic Protease Inhibitors R. Renae Speck, Charles Flexner, Chun-Juan Tian, Xiao-Fang Yu Antimicrob Agents Chemother. 2000 May; 44(5): 1397–1403. doi: 10.1128/aac.44.5.1397-1403.2000 PMCID: PMC89883 6: Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. C A Deminie, C M Bechtold, D Stock, M Alam, F Djang, A H Balch, T C Chou, M Prichard, R J Colonno, P F Lin Antimicrob Agents Chemother. 1996 Jun; 40(6): 1346–1351. PMCID: PMC163329 7: R88-APOBEC3Gm Inhibits the Replication of Both Drug-resistant Strains of HIV-1 and Viruses Produced From Latently Infected Cells Xiaoxia Wang, Zhujun Ao, Kallesh Danappa Jayappa, Bei Shi, Gary Kobinger, Xiaojian Yao Mol Ther Nucleic Acids. 2014 Mar; 3(3): e151. Published online 2014 Mar 4. doi: 10.1038/mtna.2014.2 PMCID: PMC4027983 8: Pharmacokinetics of Antiretrovirals in Mucosal Tissue M.L. Cottrell, N. Srinivas, A.D.M. Kashuba Expert Opin Drug Metab Toxicol. Author manuscript; available in PMC 2016 Jun 1.Published in final edited form as: Expert Opin Drug Metab Toxicol. 2015 Jun; 11(6): 893–905. Published online 2015 Mar 22. doi: 10.1517/17425255.2015.1027682 PMCID: PMC4498566 9: Increasing Extracellular Protein Concentration Reduces Intracellular Antiretroviral Drug Concentration and Antiviral Effect Lindsay B. Avery, Melissa A. Zarr, Rahul P. Bakshi, Robert F. Siliciano, Craig W. Hendrix AIDS Res Hum Retroviruses. 2013 Nov; 29(11): 1434–1442. doi: 10.1089/aid.2013.0031 PMCID: PMC3809607 10: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J H Condra, D J Holder, W A Schleif, O M Blahy, R M Danovich, L J Gabryelski, D J Graham, D Laird, J C Quintero, A Rhodes, H L Robbins, E Roth, M Shivaprakash, T Yang, J A Chodakewitz, P J Deutsch, R Y Leavitt, F E Massari, J W Mellors, K E Squires, R T Steigbigel, H Teppler, E A Emini J Virol. 1996 Dec; 70(12): 8270–8276. PMCID: PMC190914

View History

Belarizine

MedKoo CAT#: 592592

CAS#: 52395-99-0